Raquel Hernandez-Flores
Salamanca, CL, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
The Src inhibitor peptide TAT-Cx43266-283 improves survival in an intracranial murine model of lung cancer brain metastasis.
Journal: Neuro-oncology advances
Published: November 24, 2025
Single-nucleus RNA sequencing reveals a preclinical model for the most common subtype of glioblastoma.
Journal: Communications biology
Published: April 11, 2024
EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266-283 antitumor response in preclinical glioblastoma models.
Journal: Neuro-oncology
Published: March 20, 2024
A proteomic approach supports the clinical relevance of TAT-Cx43266-283 in glioblastoma.
Journal: Translational research : the journal of laboratory and clinical medicine
Published: March 12, 2024
Erratum to 'Connexin43 peptide, TAT-Cx43266-283, selectively targets glioma cells, impairs malignant growth, and enhances survival in mouse models in vivo'.
Journal: Neuro-oncology
Published: June 10, 2020
Targeting metabolic plasticity in glioma stem cells in vitro and in vivo through specific inhibition of c-Src by TAT-Cx43266-283.
Journal: EBioMedicine
Published: March 05, 2020
Connexin43 peptide, TAT-Cx43266-283, selectively targets glioma cells, impairs malignant growth, and enhances survival in mouse models in vivo.
Journal: Neuro-oncology
Published: December 29, 2019
Showing 1-8 of 8
Last Updated: 09/26/2026